Varian Medical Systems Company Profile (NYSE:VAR)

Varian Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "VAR."

Varian Medical Systems, Inc. (NYSE:VAR) released its earnings results on Wednesday, July, 26th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.95 by $0.09. The firm had revenue of $662.40 million for the quarter, compared to analyst estimates of $663.86 million. Varian Medical Systems had a return on equity of 24.70% and a net margin of 9.50%. The company's revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.00 EPS. View Varian Medical Systems' Earnings History.

Varian Medical Systems is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Varian Medical Systems.

Varian Medical Systems issued an update on its fourth quarter earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.15-$1.23 for the period, compared to the Thomson Reuters consensus estimate of $1.18.

10 analysts have issued 12 month price objectives for Varian Medical Systems' shares. Their predictions range from $81.50 to $106.00. On average, they expect Varian Medical Systems' share price to reach $94.94 in the next year. View Analyst Ratings for Varian Medical Systems.

Here are some recent quotes from research analysts about Varian Medical Systems stock:

• 1. According to Zacks Investment Research, "Varian Medical's oncology and Proton therapy business growth prospects remain impressive. The company is addressing both the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam, Halcyon products. Varian has been winning contracts, not only in the Americas but also in the emerging international markets, which is a huge positive. We believe China and Africa present significant top-line growth opportunity in the near term. The company is opening up new offices in Africa and the Middle East, which shows that it is aware of the growth opportunities in the region. Varian Medical posted an impressive second quarter of fiscal 2017, beating the Zacks Consensus Estimate on both the counts. The company’s upbeat guidance for the coming quarters is a positive. Share price movement in the past three months has been encouraging, trading above the broader industry." (7/13/2017)
• 2. Jefferies Group LLC analysts commented, "We hosted VAR CEO and CFO for a lunch. Key takeaways: 1) VREX spin process was all inclusive; 2) F17 RemainCo outlook calls for HSD EPS growth; 3) RadOnc outlook stable on multiple fronts near and long-term; 3) next-gen linac expected in 2H17; 5) aim is to double Software in 5-years; 6) proton stable postCTCL with glimmers of light in tunnel; and 7) at least $1.0bn in debt capacity for M&A. We are publishing revised stand-alone estimates and PT of $88." (2/8/2017)

Some companies that are related to Varian Medical Systems include Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY) and Accuray Incorporated (ARAY).

Varian Medical Systems' management team includes the folowing people:

• R. Andrew Eckert, Independent Chairman of the Board
• Dow R. Wilson, President, Chief Executive Officer
• Timothy E. Guertin, Vice Chairman of the Board
• Elisha W. Finney, Chief Financial Officer, Executive Vice President - Finance
• Gary E. Bischoping Jr., Chief Financial Officer
• Kolleen T. Kennedy, Executive Vice President and President - Oncology Systems
• John W. Kuo, Senior Vice President, General Counsel, Corporate Secretary
• Rafael Torres, Senior Vice President - Business Development and Strategy
• Jose Baselga M.D., Ph.D., Director
• Jean-Luc Butel, Director

Varian Medical Systems' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (1.82%), Nationwide Fund Advisors (0.41%), Robeco Institutional Asset Management B.V. (0.30%), BB&T Corp (0.21%), Montrusco Bolton Investments Inc. (0.11%) and PGGM Investments (0.07%). Company insiders that own Varian Medical Systems stock include Clarence R Verhoef, Dow R Wilson, Elisha W Finney, John W Kuo, Kolleen T Kennedy, Mark R Laret, R Andrew Eckert, Ruediger Naumann-Etienne, Susan L Bostrom and Timothy E Guertin. View Institutional Ownership Trends for Varian Medical Systems.

Varian Medical Systems' stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Nationwide Fund Advisors, BB&T Corp, Shell Asset Management Co., State Treasurer State of Michigan, Rockefeller Financial Services Inc., Culbertson A N & Co. Inc. and CAPROCK Group Inc.. Company insiders that have sold Varian Medical Systems stock in the last year include Dow R Wilson, John W Kuo, Kolleen T Kennedy, Mark R Laret, R Andrew Eckert, Susan L Bostrom and Timothy E Guertin. View Insider Buying and Selling for Varian Medical Systems.

Varian Medical Systems' stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Robeco Institutional Asset Management B.V., Personal Capital Advisors Corp, Carnick & Kubik Group LLC, BerganKDV Wealth Management LLC, Montrusco Bolton Investments Inc. and Mutual of America Capital Management LLC. View Insider Buying and Selling for Varian Medical Systems.

Shares of Varian Medical Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Varian Medical Systems stock can currently be purchased for approximately $107.37.